Novo Nordisk A/s (NVO)

$128.31

+1.43

(+1.13%)▲

Market is closed - opens 7 PM, 01 May 2024
star icon

Novo Nordisk A/S is a global healthcare company that specializes in the development, production, and marketing of pharmaceutical products.

Insights on Novo Nordisk A/s

  • Increasing Revenue

    Revenue is up for the last 7 quarters, 41.26B → 65.86B (in $), with an average increase of 7.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 22.47B → 21.96B (in $), with an average decrease of 2.3% per quarter

Performance

  • $127.55
    $130.43
    $128.31
    downward going graph

    0.59%

    Downside

    Day's Volatility :2.21%

    Upside

    1.63%

    downward going graph
  • $74.66
    $137.29
    $128.31
    downward going graph

    41.81%

    Downside

    52 Weeks Volatility :45.62%

    Upside

    6.54%

    downward going graph

Returns

PeriodNovo Nordisk A/sSector (Health Care)Index (Russel 2000)
3 Months
9.58%
-1.2%
0.0%
6 Months
29.89%
12.5%
0.0%
1 Year
51.57%
4.6%
0.0%
3 Years
236.82%
15.7%
-21.9%

Highlights

Market Capitalization
562.8B
Book Value
$23.9
Dividend Share
9.4
Dividend Yield
1.09%
Earnings Per Share (EPS)
2.66
PE Ratio
47.43
PEG Ratio
2.4
Wall Street Target Price
145.27
Profit Margin
36.03%
Operating Margin TTM
42.79%
Return On Assets TTM
23.39%
Return On Equity TTM
88.07%
Revenue TTM
232.3B
Revenue Per Share TTM
51.81
Quarterly Revenue Growth YOY
37.0%
Gross Profit TTM
148.5B
EBITDA
109.8B
Diluted Eps TTM
2.66
Quarterly Earnings Growth YOY
0.63
EPS Estimate Current Year
3.35
EPS Estimate Next Year
4.03
EPS Estimate Current Quarter
0.65
EPS Estimate Next Quarter
0.81

Analyst Recommendation

Buy
    54%Buy
    32%Hold
    12%Sell
Based on 31 Wall street analysts offering stock ratings for Novo Nordisk A/s(by analysts ranked 0 to 5 stars)
Based on 31 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
19
Hold
10
10
10
Sell
4
4
3

Analyst Forecast

What analysts predicted

Upside of 13.22%

Current $128.31
Target $145.27

Company Financials

FY18Y/Y Change
Revenue
17.1B
↑ 0.12%
Net Income
5.9B
↑ 1.31%
Net Profit Margin
34.54%
↑ 0.4%
FY19Y/Y Change
Revenue
18.3B
↑ 9.11%
Net Income
5.8B
↑ 0.84%
Net Profit Margin
31.92%
↓ 2.62%
FY20Y/Y Change
Revenue
21.0B
↑ 4.04%
Net Income
7.0B
↑ 8.18%
Net Profit Margin
33.19%
↑ 1.27%
FY21Y/Y Change
Revenue
21.4B
↑ 10.91%
Net Income
7.3B
↑ 13.33%
Net Profit Margin
33.92%
↑ 0.73%
FY22Y/Y Change
Revenue
25.5B
↑ 25.68%
Net Income
8.0B
↑ 16.27%
Net Profit Margin
31.38%
↓ 2.54%
FY23Y/Y Change
Revenue
34.4B
↑ 31.26%
Net Income
12.4B
↑ 50.71%
Net Profit Margin
36.03%
↑ 4.65%
Q3 FY22Q/Q Change
Revenue
6.0B
↑ 10.42%
Net Income
1.9B
↑ 8.16%
Net Profit Margin
31.61%
↓ 0.66%
Q4 FY22Q/Q Change
Revenue
6.9B
↑ 5.54%
Net Income
2.0B
↓ 5.64%
Net Profit Margin
28.26%
↓ 3.35%
Q1 FY23Q/Q Change
Revenue
7.8B
↑ 10.97%
Net Income
2.9B
↑ 45.78%
Net Profit Margin
37.13%
↑ 8.87%
Q2 FY23Q/Q Change
Revenue
8.0B
↑ 1.75%
Net Income
2.8B
↓ 1.95%
Net Profit Margin
35.78%
↓ 1.35%
Q3 FY23Q/Q Change
Revenue
58.7B
↑ 8.16%
Net Income
22.5B
↑ 15.7%
Net Profit Margin
38.27%
↑ 2.49%
Q4 FY23Q/Q Change
Revenue
9.8B
↑ 12.14%
Net Income
3.3B
↓ 2.29%
Net Profit Margin
33.35%
↓ 4.92%
FY18Y/Y Change
Total Assets
17.0B
↑ 8.22%
Total Liabilities
9.0B
↑ 12.16%
FY19Y/Y Change
Total Assets
18.8B
↑ 13.4%
Total Liabilities
10.2B
↑ 15.42%
FY20Y/Y Change
Total Assets
24.0B
↑ 15.37%
Total Liabilities
13.5B
↑ 19.96%
FY21Y/Y Change
Total Assets
29.6B
↑ 34.22%
Total Liabilities
18.8B
↑ 51.67%
FY22Y/Y Change
Total Assets
34.7B
↑ 24.03%
Total Liabilities
22.7B
↑ 27.48%
FY23Y/Y Change
Total Assets
46.6B
↑ 30.35%
Total Liabilities
30.8B
↑ 31.79%
Q3 FY22Q/Q Change
Total Assets
32.1B
↑ 10.92%
Total Liabilities
22.0B
↑ 15.01%
Q4 FY22Q/Q Change
Total Assets
34.7B
↓ 0.65%
Total Liabilities
22.7B
↓ 5.05%
Q1 FY23Q/Q Change
Total Assets
36.6B
↑ 3.63%
Total Liabilities
24.9B
↑ 7.85%
Q2 FY23Q/Q Change
Total Assets
41.2B
↑ 12.29%
Total Liabilities
27.9B
↑ 11.83%
Q3 FY23Q/Q Change
Total Assets
300.1B
↑ 6.89%
Total Liabilities
207.1B
↑ 8.84%
Q4 FY23Q/Q Change
Total Assets
46.6B
↑ 4.79%
Total Liabilities
30.8B
↑ 0.39%
FY18Y/Y Change
Operating Cash Flow
6.8B
↑ 8.38%
Investing Cash Flow
-1.9B
↑ 83.84%
Financing Cash Flow
-5.3B
↓ 3.27%
FY19Y/Y Change
Operating Cash Flow
7.0B
↑ 4.85%
Investing Cash Flow
-1.7B
↓ 4.73%
Financing Cash Flow
-5.3B
↑ 2.79%
FY20Y/Y Change
Operating Cash Flow
8.6B
↑ 11.05%
Investing Cash Flow
-3.7B
↑ 94.94%
Financing Cash Flow
-5.3B
↓ 9.13%
FY21Y/Y Change
Operating Cash Flow
8.4B
↑ 5.87%
Investing Cash Flow
-4.8B
↑ 40.87%
Financing Cash Flow
-3.9B
↓ 20.94%
FY22Y/Y Change
Operating Cash Flow
11.4B
↑ 43.43%
Investing Cash Flow
-3.6B
↓ 21.16%
Financing Cash Flow
-7.5B
↑ 103.18%
Q3 FY22Q/Q Change
Operating Cash Flow
3.2B
↑ 1.16%
Investing Cash Flow
-655.7M
↑ 18.12%
Financing Cash Flow
-1.9B
↑ 39.61%
Q4 FY22Q/Q Change
Operating Cash Flow
1.0B
↓ 70.7%
Investing Cash Flow
-3.6B
↑ 402.28%
Financing Cash Flow
-1.1B
↓ 47.35%
Q1 FY23Q/Q Change
Operating Cash Flow
4.4B
↑ 319.86%
Investing Cash Flow
-973.1M
↓ 73.32%
Financing Cash Flow
-3.0B
↑ 168.92%
Q2 FY23Q/Q Change
Operating Cash Flow
4.2B
↓ 4.15%
Investing Cash Flow
-2.3B
↑ 139.69%
Financing Cash Flow
-1.8B
↓ 38.95%
Q3 FY23Q/Q Change
Operating Cash Flow
41.0B
↑ 43.35%
Investing Cash Flow
-29.2B
↑ 83.12%
Financing Cash Flow
-19.8B
↑ 57.53%

Technicals Summary

Sell

Neutral

Buy

Novo Nordisk A/s is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Novo Nordisk A/s
Novo Nordisk A/s
-0.53%
29.89%
51.57%
236.82%
416.51%
Moderna, Inc.
Moderna, Inc.
5.7%
46.48%
-16.33%
-40.0%
322.8%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.93%
12.79%
10.63%
82.65%
161.89%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.77%
7.28%
14.84%
81.78%
129.55%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
416.51%
47.43
36.03%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
322.8%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
161.89%
26.04
30.14%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
129.55%
28.81
36.68%

Institutional Holdings

  • Jennison Associates LLC

    0.50%

  • Fisher Asset Management, LLC

    0.32%

  • Renaissance Technologies Corp

    0.31%

  • Bank of America Corp

    0.29%

  • FMR Inc

    0.28%

  • Fayez Sarofim & Company

    0.26%

Corporate Announcements

  • Novo Nordisk A/s Dividends March,2024

    In the quarter ending March,2024. Novo Nordisk A/s has declared dividend of $0.93

    Read More

Company Information

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.

Organization
Novo Nordisk A/s
Employees
63370
CEO
Mr. Lars Fruergaard Jorgensen
Industry
Health Technology

Discover More

FAQs